title: A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome.
abstract: OBJECTIVE
  To systematically review the impact of Yasmin (drospirenone pill) compares with other standard treatments for symptoms of Polycystic Ovary Syndrome (PCOS).
  
  
  METHODS
  The relevant studies of the randomized controlled trials in women with PCOS treated with drospirenone were retrieved and the systematic evaluation was conducted.
  
  
  RESULTS
  Eighteen articles were included. Compared with drospirenone (DRSP) monotherapy, DRSP plus metformin was better in reducing body mass index (BMI), luteinizing hormone (LH) and low-density lipoprotein cholesterol (LDL-C). Compared with metformin, DRSP was better in modulating serum total testosterone (T), sex hormone-binding globulin (SHBG), follicle stimulating hormone (FSH) and free androgen index (FAI), while metformin was more effective in reducing BMI, total cholesterol (TC), LDL-C and Triglyceride (TG). DRSP was superior to cyproterone acetate (CPA) in reducing TC and homeostasis model assessment of insulin resistance (HOMA-IR). DRSP shows better effect in modulating LDL-C and high-density lipoprotein cholesterol (HDL-C) compared with desogestrel (DSG).
  
  
  CONCLUSIONS
  The available data suggested that DRSP was effective in modulating hormones, insulin and lipid metabolism in women with PCOS. Compared with commonly used drugs for symptoms of PCOS as CPA and DSG, DRSP shows identical or better effect in improving symptoms and protect cardiovascular system. For the PCOS patients with IR, obesity or high LH/FSH ratio, DRSP combines with metformin maybe more effective than use DRSP alone.
authors.affiliation: College of Pharmacy, Southwest University for Nationalities, No.16 South 4th Section, 1st Ring Road, Chengdu, Sichuan 610041, PR China. Electronic address: 27918716@qq.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: Chengdu Univeisity, Sichuan Industrial Institute of Antibiotics, No.168 Huaguan Road, Longtan Industrial Park, Chengdu, Sichuan 610041, PR China. Electronic address: 26690476@qq.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Ren
authors.affiliation: Chengdu Univeisity, Sichuan Industrial Institute of Antibiotics, No.168 Huaguan Road, Longtan Industrial Park, Chengdu, Sichuan 610041, PR China. Electronic address: 1509614685@qq.com.
authors.forename: Wenxia
authors.initials: W
authors.lastname: Sun
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000736:Androstenes / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D000736:Androstenes; D007004:Hypoglycemic Agents; D000451:Mineralocorticoid Receptor Antagonists; D017373:Cyproterone Acetate; D008687:Metformin; C035144:drospirenone
keywords: Drospirenone; Meta-analysis; PCOS; Systematic review